Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme that plays a key role in regulating the circulating low density lipoprotein cholesterol (LDL-C). Among the PCSK9 variants, while gain-of-function mutations aggravate the degradation of LDL receptors, leading to familial hypercholesterolemia (FH), whereas loss-of-function mutations increase LDL receptor levels, lower LDL levels, and prevent coronary heart disease. The variants of PCSK9 have not been clarified in the Vietnamese population yet. Hence, the present study aimed to present the molecular characteristics of PCSK9 gene in Vietnamese hypercholesterolemia patients. A total of 26 peripheral blood samples were collected from the patients who were diagnosed with Hypercholesterolemia in a local hospital. The PCR-sequencing method was applied to amplify and sequencing PCSK9. Then, variant screening was performed by comparing with the reference sequence (NG_009061). 60 variants were identified in 14 of 26 patients (accounting for 53.85%): 50 (83.33%) variants were identified as novel variants among which, 24 were probably damaging, 11 were benign, and 15 were variants of uncertain significance. Functional effects of novel variants were predicted by using PolyPhen-2 and FSPLICE. This study analyzed the variants spectrum in Vietnamese Hypercholesterolemia patients and expresses the importance of genetic diagnosis in FH patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.